| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Mevalonic acid targets the mevalonate pathway downstream of HMG-CoA reductase (HMGCR). By bypassing HMGCR, it serves as a substrate for mevalonate kinase and subsequent enzymes. It is used to reverse the effects of statin-mediated HMGCR inhibition and to study isoprenoid biosynthesis.
|
|---|---|
| ln Vitro |
Mevalonic acid lithium salt (80, 90, 100, and 110 µM; 72 hours) prevents the loss of viability of C2C12 myotube cells caused by simvastatin in vitro[1].
In vitro, mevalonic acid (80-110 uM) rescues cell death induced by statins (e.g., simvastatin) in C2C12 myoblasts. It stimulates DNA synthesis, morphology transformation, and cell cycling in human lymphocytes. It is used as a standard to study lipid metabolism and statin pharmacology. |
| ln Vivo |
In vivo, mevalonic acid lithium salt is used to investigate the mevalonate pathway in animal models of metabolic disease and cancer. It can reverse statin-induced effects when co-administered. It is also studied for its role in cholesterol synthesis and isoprenoid metabolism.
|
| Enzyme Assay |
Non-cell assays use purified mevalonate kinase enzyme with mevalonic acid as substrate. The reaction produces mevalonate-5-phosphate, and activity is measured by coupling to pyruvate kinase/lactate dehydrogenase (PK/LDH) to monitor NADH oxidation at 340 nm, or by LC-MS detection of the phosphorylated product.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: C2C12 cells ( simvastatin-induced) Tested Concentrations: 80, 90, 100, 110 µM Incubation Duration: 72 h Experimental Results: demonstrated no decline in cell viability. For cell studies, mevalonic acid lithium salt is dissolved in culture medium (0.1-1 mM) and added to cells (e.g., C2C12 myoblasts, primary human lymphocytes). Effects on cell viability (MTT), proliferation (BrdU), and cholesterol synthesis (by LC-MS) are assessed. It is also used to study protein geranylgeranylation. |
| Animal Protocol |
In animal studies, mevalonic acid lithium salt is typically administered to rodents by intraperitoneal injection (50-200 mg/kg) or oral gavage. Blood and tissue samples are collected to analyze cholesterol, isoprenoid, and dolichol levels. It is also used in combination with statins in pharmacological studies.
|
| ADME/Pharmacokinetics |
Mevalonic acid is rapidly converted to mevalonate-5-phosphate by mevalonate kinase, then further metabolized to isopentenyl pyrophosphate (IPP). The lithium salt improves solubility and stability. The compound has a short plasma half-life (≈30 minutes) and is water-soluble, facilitating formulation for in vivo use.
|
| Toxicity/Toxicokinetics |
Mevalonic acid is non-toxic at physiological concentrations. The lithium salt form carries the toxicity profile of lithium ions at high doses, including nephrotoxicity and neurotoxicity. At typical research doses, it is considered safe for laboratory use with standard precautions.
|
| References |
[1]. Moschetti A, et al. Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. Nanomedicine. 2021 Oct;37:102439.
[2]. Soma MR, et al. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett. 1992 Dec;64-65 Spec No:1-15. |
| Additional Infomation |
Mevalonic acid lithium salt is a research tool for studying the mevalonate pathway, statin pharmacology, cholesterol biosynthesis, and isoprenoid metabolism. It is not an approved pharmaceutical. It is also used as a substrate for mevalonate kinase assays and as a standard in metabolomics studies.
|
| Molecular Formula |
C6H13LIO4
|
|---|---|
| Molecular Weight |
156.106022596359
|
| Exact Mass |
154.081
|
| CAS # |
2618458-93-6
|
| Related CAS # |
Mevalonic acid;150-97-0
|
| PubChem CID |
76224943
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
11
|
| Complexity |
128
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C(=O)O)C(O)(C)CCO.[LiH]
|
| InChi Key |
PVWNXFFXFNEHDZ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C6H12O4.Li/c1-6(10,2-3-7)4-5(8)9;/h7,10H,2-4H2,1H3,(H,8,9);/q;+1/p-1
|
| Chemical Name |
lithium;3,5-dihydroxy-3-methylpentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~648.97 mM)
DMSO :~50 mg/mL (~324.49 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (16.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (648.97 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4057 mL | 32.0287 mL | 64.0574 mL | |
| 5 mM | 1.2811 mL | 6.4057 mL | 12.8115 mL | |
| 10 mM | 0.6406 mL | 3.2029 mL | 6.4057 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
